After 12 months of bitter negotiations, merger talks between three Australian pharmaceutical wholesalers - QDL Ltd, Australian Pharmaceutical Industries and Sigma Ltd - have broken down, opening up the likelihood of another price war in the sector.
The three had hoped to form a national company which could be listed on the stock exchange, and represent a substantial competitive force to F H Faulding. The merger talks failed as the companies could not reach agreement on points such as composition of the board, capital gains tax and goodwill associated with API's and Sigma's cooperative status.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze